Castle Biosciences (CSTL) Operating Income: 2018-2025
Historic Operating Income for Castle Biosciences (CSTL) over the last 8 years, with Sep 2025 value amounting to -$6.8 million.
- Castle Biosciences' Operating Income fell 233.96% to -$6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.9 million, marking a year-over-year decrease of 3265.41%. This contributed to the annual value of $8.7 million for FY2024, which is 112.75% up from last year.
- Latest data reveals that Castle Biosciences reported Operating Income of -$6.8 million as of Q3 2025, which was down 60.06% from -$4.3 million recorded in Q2 2025.
- In the past 5 years, Castle Biosciences' Operating Income registered a high of $5.1 million during Q3 2024, and its lowest value of -$31.5 million during Q1 2023.
- Its 3-year average for Operating Income is -$8.9 million, with a median of -$5.7 million in 2023.
- In the last 5 years, Castle Biosciences' Operating Income plummeted by 1,265.89% in 2021 and then soared by 171.58% in 2024.
- Castle Biosciences' Operating Income (Quarterly) stood at -$15.2 million in 2021, then crashed by 50.50% to -$22.8 million in 2022, then spiked by 75.22% to -$5.7 million in 2023, then surged by 171.58% to $4.0 million in 2024, then plummeted by 233.96% to -$6.8 million in 2025.
- Its Operating Income stands at -$6.8 million for Q3 2025, versus -$4.3 million for Q2 2025 and -$27.9 million for Q1 2025.